CLINICAL_TRIALS
trial_result
· 2021-09-09
Clinical Trial Update: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) [Phase 2]
Summary
A Phase 2 trial evaluating a dendritic cell/myeloma fusion vaccine for multiple myeloma has completed enrollment, with results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-09